Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propranolol
Drug ID BADD_D01867
Description Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
Marketing Status approved; investigational
ATC Code C07AA05
DrugBank ID DB00571
KEGG ID D08443
MeSH ID D011433
PubChem ID 4946
TTD Drug ID D04JEE
NDC Product Code Not Available
UNII 9Y8NXQ24VQ
Synonyms Propranolol | Propanolol | Inderal | Avlocardyl | AY-20694 | AY 20694 | AY20694 | Rexigen | Dexpropranolol | Dociton | Obsidan | Obzidan | Propranolol Hydrochloride | Hydrochloride, Propranolol | Anaprilin | Anapriline | Betadren
Chemical Information
Molecular Formula C16H21NO2
CAS Registry Number 525-66-6
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Wheezing22.03.01.0090.002046%
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Mental status changes19.07.01.0010.000267%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.0070.000214%Not Available
Hypoglycaemic seizure17.12.03.015; 14.06.03.002; 05.06.03.0020.000481%Not Available
Hypoacusis04.02.01.006--
Paradoxical drug reaction08.06.01.0140.000240%Not Available
Brain death17.02.03.003; 08.04.01.0040.000053%Not Available
General physical health deterioration08.01.03.0180.000347%Not Available
Bradyarrhythmia02.03.02.0150.000053%Not Available
Left ventricular hypertrophy02.04.02.0140.000053%Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Dysstasia15.03.05.011; 17.02.02.012; 08.01.03.0890.000053%Not Available
Tonic clonic movements17.12.03.0060.000053%Not Available
Fluid imbalance14.05.01.0030.000053%Not Available
Exercise tolerance decreased08.01.03.0360.000187%Not Available
Pneumatosis08.01.03.0440.000053%Not Available
Haemodynamic instability24.03.02.0060.000134%Not Available
Eye pruritus06.04.05.0060.000182%Not Available
Ocular discomfort06.08.03.0080.000053%Not Available
Respiratory tract congestion22.02.07.0030.000182%Not Available
Lymphatic disorder01.09.01.003--Not Available
Drug tolerance08.06.01.003--Not Available
Affect lability19.04.01.001--Not Available
Cerebral disorder17.02.10.0170.000160%Not Available
Varices oesophageal24.10.02.004; 07.15.05.001; 09.01.06.0090.000107%Not Available
Pneumatosis intestinalis07.11.01.0430.000134%Not Available
Temperature intolerance08.01.09.0220.000171%Not Available
Urine odour abnormal20.02.01.0200.000182%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
The 11th Page    First    Pre   11 12 13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene